Clinical trials: Urologic Diseases
Type 2 Diabetes Mellitus
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
The investigators hypothesize that Cana may be able to improve number and function of CD34+ endothelial progenitor cells. The investigators also propose that this expected cardiovascular benefit is independent of HbA1C reduction.
- Trial name
- NCT02964585
- Testing
- Canagliflozin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- George Washington University
Renal Cell Cancer
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
This research study is for subjects with cancer of the kidney (also known as renal cell carcinoma) that cannot be treated with surgery.
- Trial name
- NCT00184015
- Testing
- Bevacizumab and Bortezomib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Southern California
Spinal Cord Injury (SCI), Neurogenic Bladder (NB)
Home Neuromodulation for Neurogenic Bladder Management in Spinal Cord Injury
The purpose of this study is to determine the safety and efficacy of Injectrode Tibial Nerve Stimulation for bladder function in people with spinal cord injury.
- Trial name
- NCT07264868
- Testing
- iTNS
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Health Science Center, Houston
Kidney Stones
A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones
Patients who present for the first time to Emergency Room with renal colic due to a distal ureteral calculus (as diagnosed with spiral CT scan and KUB) will be randomized to receive Xatral 10mg po once a day or placebo once…
- Trial name
- NCT00583258
- Testing
- Alfuzosin (Xatral)
- Where
- Canada
- Sponsor
- Unity Health Toronto
Hypotension, Brain Injuries
Correlation Between Circulating Biomarkers of Organs Damage and Intraoperative Hypotension Management
Intraoperative hypotension (defined as mean arterial pressure below 65 mmHg) is associated with increased organs dysfunction and mortality.
- Conditions
- Hypotension, Brain Injuries, Renal Failure, Endothelial Dysfunction
- Trial name
- NCT03527758
- Testing
- Flo TracIQ with HPI software
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Catania
Urinary Incontinence, Urinary Incontinence, Stress
Pelvic Floor Rehabilitation Programme for Women With Urinary Incontinence in a Peruvian Public Hospital
This study evaluates whether a 12-week pelvic floor rehabilitation programme improves urinary incontinence symptoms in adult women treated at Hospital Nacional Edgardo Rebagliati Martins, a public tertiary hospital in Lima, Peru.
- Conditions
- Urinary Incontinence, Urinary Incontinence, Stress, Urinary Incontinence, Urge, Mixed Urinary Incontinence
- Trial name
- NCT07858968
- Testing
- Supervised group pelvic floor muscle training, Individual physiatrist-led pelvic floor sessions
- Where
- Peru
- Volunteers
- 89 people
- Sponsor
- Hospital Nacional Edgardo Rebagliati Martins
Acute Kidney Injury
Strategy for Uptake of Processes for Recognizing and Responding to Acute Kidney Injury
Acute kidney injury (AKI) is common and costly complication of major surgery. AKI can lead to prolonged hospitalization and a higher likelihood of dialysis, chronic kidney disease and death.
- Trial name
- SUPPORT AKI (NCT03564314)
- Testing
- SUPPORT AKI Clinical Decision Support
- Where
- 4 sites in Canada
- Volunteers
- 2,135 people
- Sponsor
- University of Calgary
Renal Impairment
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
The primary objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with normal renal function and participants with various degrees of renal impairment.
- Trial name
- NCT05489614
- Testing
- Olpasiran
- Where
- 6 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Amgen
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
SLM + Axitinib for Clear Cell RCC
This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it…
- Trial name
- NCT02535533
- Testing
- Selenomethionine (SLM), Axitinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mohammed Milhem
ESRD, Anticoagulant Toxicity
Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
Apixaban is a novel oral direct factor Xa inhibitor; In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality (the…
- Trial name
- NCT03456648
- Testing
- apixaban
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Bladder Cancer, Entire Ileal Conduit
Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy
The process of enhancing the functional capacity of an individual before an operation to enable him or her to withstand the stress of surgery has been termed prehabilitation.
- Conditions
- Bladder Cancer, Entire Ileal Conduit, Urinary Bladder Cancer
- Trial name
- NCT01836978
- Testing
- Prehabilitation
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Carcinoma, Renal Cell
Study of SU011248 in Patients With Advanced Kidney Cancer
To determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with metastatic Renal Cell Cancer (RCC).
- Trial name
- NCT00254540
- Testing
- SU011248 capsule
- Where
- 11 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Pfizer
Acute Renal Failure, Dialysis Related Complication
Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study
The aim of the study are: 1) To evaluate the occurrence of acid-base alterations and the incidence of hypophosphatemia during different modalities of Renal Replacement Terapy (RRT) in critically ill patients [CVVH, CVVHDF and…
- Conditions
- Acute Renal Failure, Dialysis Related Complication, Hypophosphatemia, Hypomagnesemia
- Trial name
- NCT03976440
- Testing
- Renal Replacement Therapy (RRT) start
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Parma
Chronic Kidney Disease
Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)
The purpose of this study is to look at subject incidence of adverse events.
- Trial name
- NCT00156962
- Testing
- Epoetin alfa DT, Epoetin alfa RB
- Volunteers
- 850 people
- Sponsor
- Amgen
Kidney Cancer
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
RATIONALE: Biological therapies, such as interferon alfa-2b, may interfere with the growth of tumor cells. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00072046
- Testing
- bevacizumab, recombinant interferon alfa
- Where
- 493 sites in United States, Canada
- Volunteers
- 732 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer
Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00032188
- Testing
- aldesleukin, bryostatin 1, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Axitinib Therapy Management Study
The objectives of the study is to describe axitinib therapy management through use of the data to be generated by ConcertAI
- Trial name
- NCT04555603
- Testing
- Inlyta, Bavencio, Keytruda
- Where
- United States
- Sponsor
- Pfizer
Chronic Kidney Disease, Type II Diabetes
Heart-Kidney-Diabetes Multidisciplinary Care MOdels for CardiovascuLar Health In Patients With Chronic Kidney DiSease and Diabetes: A PragmaTIC Cluster Randomized Controlled Trial (HOLISTIC)
Our overarching goal of this study is to provide rigorous evidence for using an accelerated risk-based approach to implementing guideline directed medical therapies (GDMT) using a multidisciplinary care model (MCM) versus a usual…
- Trial name
- HOLISTIC (NCT07811427)
- Testing
- The intervention with the MCM is Kidney-Heart GDMT initiation and titration for dose optimization (as clinically tolerated), within 4 months of enrollment in the study.
- Volunteers
- 570 people
- Sponsor
- Baim Institute for Clinical Research
Healthy, Chronic Kidney Diseases
A Study of Renal Microvessel Imaging for Chronic Kidney Disease
The purpose of this research is to study the efficacy of ultrasound microvessel imaging for evaluation of Chronic Kidney Disease.
- Trial name
- NCT05764642
- Testing
- Definity, Super-resolution ultrasound imaging
- Where
- 2 sites in United States
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common hereditary renal disease, responsible for 8% to 10% of the cases of end stage renal disease (ESRD) in Western countries.
- Trial name
- ALADIN (NCT00309283)
- Testing
- Long-acting somatostatin, Saline solution
- Where
- 5 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.